Innoviva event recap and why it matters for shareholders

Innoviva (INVA) has attracted fresh attention after launching Nortiva Bio, a clinical-stage subsidiary built around the LYNX long-acting oral drug platform, alongside a new XACDURO distribution and licensing agreement with Dr. Reddy's Laboratories.

Against this backdrop, Innoviva’s share price return of 18.62% year to date and 10.04% 1 month share price return point to building momentum, while the 85.15% 3 year total shareholder return underscores how longer term holders have been rewarded.

If you are weighing where to look next in healthcare and biotech, this is a good time to scan for other opportunities using our screener of 39 healthcare AI stocks

With Innoviva trading at $23.57 and sitting about 51% below the average analyst price target of $35.50, plus a reported intrinsic discount of around 59%, investors have to ask: is there real value here or is the market already factoring in future growth?

Price-to-Earnings of 3.4x: Is it justified?

On simple numbers, Innoviva looks inexpensive, with a P/E of 3.4x compared with both peers at 16.2x and the broader US pharmaceuticals industry at 15.1x.

The P/E ratio compares what investors are paying per share to the company’s earnings per share, and it is widely used for profitable healthcare and biotech companies. A lower P/E can indicate that the market is assigning a lower value to each dollar of earnings relative to peers, which may reflect caution about the durability or quality of those earnings.

For Innoviva, the low P/E sits alongside several mixed signals. Earnings have declined by an average of 9.9% per year over the past 5 years and are forecast to decline by about 22.3% per year over the next 3 years, which may help explain why the market is not assigning a higher multiple. At the same time, the company has recently become profitable, carries a high reported Return on Equity of 37.6%, and our DCF work suggests the share price is trading at a 59.1% discount to an estimated future cash flow value, so there is a clear gap between what the SWS DCF model implies and what the current P/E suggests the market is prepared to pay.

Compared with the US pharmaceuticals industry average P/E of 15.1x, Innoviva’s 3.4x multiple is far lower, which is a strong relative discount. Against an estimated fair P/E of 8x, the current multiple is also well below a level that regression analysis suggests the market could move towards if earnings quality and outlook were viewed more in line with peers.

Result: Price-to-Earnings of 3.4x (UNDERVALUED)

However, Innoviva’s recent net income decline of 22.3% annually and reliance on a focused infectious disease portfolio could challenge sentiment if earnings or product uptake fall short of expectations.

Another view on Innoviva using the SWS DCF model

While Innoviva screens cheaply on a 3.4x P/E, the SWS DCF model goes further, suggesting the stock is trading about 59.1% below an estimated future cash flow value of $57.69 per share. If both signals point to value, the key question is what risk the market is still pricing in.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Innoviva for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 44 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Given the mixed signals around Innoviva, the key question is how you view the balance of risk and reward today. Take a closer look at the numbers, recent news and valuation work, then round out your view with 3 key rewards and 3 important warning signs

Looking for more investment ideas beyond Innoviva?

If Innoviva has sharpened your appetite for opportunity, do not stop here. Broaden your watchlist with focused stock ideas that fit different risk and income preferences.

• Target potential mispricing by reviewing a curated set of value opportunities through the 44 high quality undervalued stocks.
• Strengthen your income stream by scanning companies that feature robust yields using the 8 dividend fortresses.
• Put capital to work in companies with resilient profiles by assessing the 71 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.